- NeOnc Technologies Holdings (NASDAQ: NTHI) joins the Russell Microcap® Index following the 2025 annual reconstitution.
- Phase II clinical trials for NEO100™ and NEO212™ therapeutics are advancing with FDA Fast-Track status.
- Strategic expansion planned in the MENA region through a proposed partnership with Quazar.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company developing treatments for central nervous system (CNS) cancers, has been included in the Russell Microcap® Index after the latest 2025 annual reconstitution. This positions NeOnc among select companies with market capitalizations ranging from $30 million to $3 billion, representing the bottom 2-3% of the U.S. equity market by capitalization.
This inclusion offers NeOnc increased visibility among institutional investors and integration into growth and value style indexes used as benchmarks for approximately $10.6 trillion in assets. The membership will remain in place until the next annual reconstitution.
NeOnc is advancing two Phase II clinical trials for its proprietary therapeutics, NEO100™ and NEO212™, both of which possess FDA Fast-Track and IND status. These drugs are designed to overcome the blood-brain barrier in treating CNS cancers, and they are protected by patents extending through 2038.
The company is also seeking strategic expansion within the MENA region, with a proposed partnership with Quazar in the GCC to facilitate this growth. This partnership aims to enhance clinical trials and market presence in the region.
